Tuberculosis: Pharmacognosy, Medicinal Plant Raw Materials, Medicinal Plants, Phytotherapy
DOI:
https://doi.org/10.53933/sspmpm.v4i1.130Keywords:
tuberculosis, medicinal plant raw materials, medicinal plants, pharmacotherapy, phytotherapy, pharmacognosy, resource scienceAbstract
The article delves into the crucial role that medicinal plants could play in combating tuberculosis, highlighting their vast diversity and their proven efficacy in health preservation. As the quest for effective drugs advances, there's a growing emphasis on harnessing both unique chemical compounds and natural plant-based components. This innovative approach opens up new avenues in battling the infection caused by Mycobacterium tuberculosis. The piece underscores the significance of continued investigation into the medicinal use of plants as adjunctive therapies in tuberculosis treatment. One of the key challenges identified is the complex interaction between antituberculosis medications and herbal components, an area that remains largely unexplored. The intricacies of how these interactions occur and their impact on the effectiveness of treatment are still not well understood. The article points out that meticulous and detailed research is essential for unlocking the potential of active biomolecules found in plants, which could pave the way for the development of novel therapeutic agents. Furthermore, it stresses the importance of conducting comprehensive evaluations regarding the interactions and safety of these plant-derived substances under various experimental setups. Such research is not only pivotal for enhancing our understanding of the synergistic effects between pharmaceuticals and plant-based compounds but also for ensuring the safety and efficacy of new treatments. By focusing on these aspects, the scientific community can make significant strides in identifying and utilizing natural resources in the fight against tuberculosis, potentially leading to more effective and safer treatment options.
References
Shapovalova V. Forensic and pharmaceutical risks in the organization of pharmacotherapy of covid, post-covid and long-covid disorders. COVID-19 and vaccination practice standards. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No. 4. P. 1–24. URL: https://doi.org/10.53933/sspmpm.v2i4.69. DOI: https://doi.org/10.53933/sspmpm.v2i4.69
Shapovalova V. The ICD-11 for the twenty-first century: the first view from the organizational, legal, clinical and pharmacological aspects. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No. 1. Р. 1-13. URL: https://doi.org/10.53933/sspmpm.v2i1.37. DOI: https://doi.org/10.53933/sspmpm.v2i1.37
Shapovalov V., Osyntseva A., Shapovalov V. Organization of pharmaceutical business, drug technology, forensic and clinical pharmacy: multidisciplinary innovative nanotechnologies in the development and implementation of new medical products to medical and pharmaceutical practice. SSP Modern Pharmacy and Medicine. 2022. Vol.2. No.3. P.1-18. URL: https://doi.org/10.53933/sspmpm.v2i3.61. DOI: https://doi.org/10.53933/sspmpm.v3i1.83
Vovk D., Puhach O., Bachynska L. et al. The Role of the general practitioner-family doctor in the pharmacotherapy of Tuberculosis during the war. SSP Modern Pharmacy and Medicine. 2023. Vo.3. No.3. P.1-7. URL: https://doi.org/10.53933/sspmpm.v3i3.102. DOI: https://doi.org/10.53933/sspmpm.v3i3.102
Shapovalov В., Shapovalova В., Osyntseva А. et al. Development of the educational program of the second (master’s) level of higher education in the field of knowledge 22 Healthcare specialty 226 Pharmacy, industrial pharmacy specialization 226.01 Pharmacy based on the new standard of higher education. Actual Problems of Medicine and Pharmacy. 2023. Vol.4. N.1. P.1-47. URL: https://doi.org/10.52914/apmp.v4i1.54. DOI: https://doi.org/10.52914/apmp.v4i1.54
Shapovalov V.V., Shapovalova V.O., Tkachenko V.G. et al. Work program of the cycle of thematic improvement "Tuberculosis: medical and pharmaceutical assistance, legal support". DZ "LDMU". Approved (protocol No. 4 dated April 10, 2023). 2023. 12 p.
Shapovalova V.O., Shapovalov V.V., Osintseva A.O. et al. Working program of normative educational component 26 "Pharmacognosy". Rivne: DZ "LDMU". 2023. 19 p. (Minutes of the meeting of the university council on the quality of education dated August 31, 2023, No. 1).
Osyntseva A.O., Shapovalova V.O., Shapovalov V.V. Work program of normative educational component 32 "Resource science of medicinal plants". Rivne: DZ "LDMU". 2023. 18 p. (Minutes of the meeting of the university council on the quality of education dated August 31, 2023, No. 1).
Kyslychenko V.S., Zhuravel I.O., Marchyshyn S.M. Pharmacognosy. Kharkiv: NFaU, 2015. 736 p.
Tkachenko V.G., Shapovalova V.O., Shapovalov V.V. et al. A collection of preparation materials for the unified state qualification exam (UEKI) on the educational component of Pharmacognosy. Rivne: DZ "LDMU" 2023. 36 p. (Protocol No. 2 dated September 26, 2023).
Shapovalova V.O., Shapovalov V.V., Osintseva A.O. Materials for ensuring the final control of the educational component Pharmacognosy. Rivne: DZ "LDMU" 2023. 36p. (Protocol No. 1 dated August 31, 2023). DOI: https://doi.org/10.52422/23077832_2023_1_31
Shapovalova V.O., Shapovalov V.V., Okseniuk O.E. et al. Work program of the pre-certification cycle in the specialty "Pharmacy". Rivne: DZ "LDMU". 2023. 18 p. (Minutes of the academic council meeting dated October 26, 2023 No. 3).
Tuberculosis treatment: coverage and outcomes. WHO. 2022. URL: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/tb-diagnosis---treatment/tb-treatment-and-treatment-coverage.
Shapovalova V.A., Zbrozhek S.I., Shapоvalov V.V. et al. Coronavirus disease pandemia 2019: growth of epidemic dangers. Acta scientific pharmaceutical sciences. 2020. Vol. 4. Iss. 7. P. 61–68. URL: https://www.actascientific.com/ASPS/ASPS-04-0559.php. DOI: https://doi.org/10.31080/ASPS.2020.04.0559
Shapovalov (Jr.) V., Shapovalova V., Gudzenko A. et al. Organizational and legal analysis of the pharmaceutical provision for the most common diseases of society. International Journal of Pharmaceutical Sciences Review and Research. 2018. Vol.51. Nо.1. P. 118-124. URL: http://globalresearchonline.net/journalcontents/v51-1/18.pdf.
Shapovalova V. An Innovative multidisciplinary study of the availability of coronavirus vaccines in the world. SSP Modern Pharmacy and Medicine. 2022. Vol.2. Nо.2. P.1-17 URL: https://doi.org/10.53933/sspmpm.v2i2.45. DOI: https://doi.org/10.53933/sspmpm.v2i2.45
Shapovalova V. Monkeypox virus – new challenges of modernity: experimental organizational and legal, clinical and pharmacological studies. SSP Modern Pharmacy and Medicine. 2022. Vol.2. N.3. P.1-15. URL: https://doi.org/10.53933/sspmpm.v2i3.54. DOI: https://doi.org/10.53933/sspmpm.v2i3.54
Shapovalova V., Osyntseva A., Shapovalov V. et al. Pharmacognostic, forensic and pharmaceutical, organizational and legal, clinical and pharmacological multidisciplinary study with an assessment of peculiarities of circulation (use) of smoking mixtures of spices and entheogens of Amanita Muscaria Mushroom. SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.3. P.1-13. URL: https://doi.org/10.53933/sspmpm.v3i3.105. DOI: https://doi.org/10.53933/sspmpm.v3i3.105
Osyntseva A., Shapovalov V. Management and marketing of circulation of first-line antituberculosis medicines: use of innovative research technologies. SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.4. P.1-13. URL: https://doi.org/10.53933/sspmpm.v3i4.114. DOI: https://doi.org/10.53933/sspmpm.v3i4.114
World Health Organization. URL: https://www.who.int/news-room/questions-and-answers/item/monkeypox.
Parrish N., Dick J., Bishai W. Mechanisms of latency in Mycobacterium tuberculosis. Trends in Microbiology. 1998. Vol. 6. Iss. 3. P. 107-112. doi: https://doi.org/10.1016/S0966-842X(98)01216-5. DOI: https://doi.org/10.1016/S0966-842X(98)01216-5
Arend S., Thijsen S., Leyten E. et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. American Journal of Respiratory & Critical Care Medicine. 2007. No.175. P. 618-627. DOI: https://doi.org/10.1164/rccm.200608-1099OC
Sharifi-Rad J., Salehi B., Stojanović-Radić Z.Z. et al. Medicinal plants used in the treatment of tuberculosis - Ethnobotanical and ethnopharmacological approaches. Biotechnology Advances. 2020. Vol. 44. Р. 107629. URL: https://www.sciencedirect.com/science/article/abs/pii/S0734975020301312. DOI: https://doi.org/10.1016/j.biotechadv.2020.107629
Li T., Shewade H.D., Soe K.T. et al. Under-reporting of diagnosed tuberculosis to the national surveillance system in China: an inventory study in nine counties in 2015. BMJ Open. 2019. Vol. 9. No 1. Р. e021529. DOI: https://doi.org/10.1136/bmjopen-2018-021529. DOI: https://doi.org/10.1136/bmjopen-2018-021529
Okada K., Mao T., Mori T. et al. Performance of an interferon-gamma release assay for diagnosing latent tuberculosis infection in children. Epidemiology & Infection. 2008. No. 136. P. 1179-1187. DOI: https://doi.org/10.1017/S0950268807009831
Mangwani N., Singh P.K., and Kumar V. Medicinal plants: Adjunct treatment to tuberculosis chemotherapy to prevent hepatic damage. J. Ayurveda Integr. Med. 2020. Vol. 11. No. 4. Р. 522-528. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772497/. DOI: https://doi.org/10.1016/j.jaim.2019.02.004
Getachew S., Medhin G., Asres A. et al.Traditional medicinal plants used in the treatment of tuberculosis in Ethiopia: A systematic review. Heliyon. 2022. Vol. 8. No.5. Р. e09478. URL: https://pubmed.ncbi.nlm.nih.gov/35647341/. DOI: https://doi.org/10.1016/j.heliyon.2022.e09478
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Alina Osyntseva
This work is licensed under a Creative Commons Attribution 4.0 International License.
